Leukemias and lymphomas: Treatment and prophylaxis of the central nervous system

被引：8

作者：

Franklin J.L. ^{[1
]}

Finlay J. ^{[1
]}

机构：

[1] Children's Hospital Los Angeles, Los Angeles, CA 90027

来源：

Current Treatment Options in Neurology | 2006年 / 8卷 / 4期

关键词：

Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Main Drug Interaction; Primary Central Nervous System Lymphoma; Central Nervous System Disease;

D O I：

10.1007/s11940-006-0023-9

中图分类号：

学科分类号：

摘要：

Central nervous system (CNS)-directed therapy is required for many acute leukemia patients and for nearly all aggressive or high-grade non-Hodgkin's lymphoma patients as part of an overall chemotherapy plan for disease eradication. The CNS therapy decisions differ for overt disease treatment versus prophylactic treatment and take into consideration the type of leukemia or lymphoma, the age of the patient, and other prognostic factors. A variety of CNS-directed therapies are used for prevention or treatment of CNS disease in acute leukemias or aggressive lymphomas: intrathecal medications (cytosine arabinoside, methotrexate, or both in combination with hydrocortisone) with or without cranial or craniospinal irradiation, intrathecal medication only with intensive systemic chemotherapy, or high-dose chemotherapy specifically chosen for CNS penetrance. Any type of CNS-directed therapy, whether intrathecal chemotherapy, high-dose systemic chemotherapy, or irradiation, may cause acute or delayed (late) toxicity. Ongoing clinical trial research aims to reduce the risk of toxicity from CNS-directed therapy while preserving or improving treatment efficacy. Copyright © 2006 by Current Science Inc.

引用

页码：335 / 345

页数：10

共 61 条

[31]

Abbott B.L., Rubnitz J.E., Tong X., Et al., Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: A single institutions experience, Leukemia, 17, pp. 2090-2096, (2003)

[32]

Bisschop M.M., Revesz T., Bierings M., Et al., Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukemia, Leukemia, 15, pp. 46-49, (2001)

[33]

Cassileth P.A., Sylvester L.S., Bennett J.M., Et al., High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia, J Clin Oncol, 6, pp. 495-500, (1988)

[34]

Bishop J.F., Matthews J.P., Young G.A., Et al., A randomized study of high dose cytarabine in induction in acute myeloid leukemia, Blood, 87, pp. 1710-1717, (1996)

[35]

Herzig R.H., High dose ara-C in older adults with acute leukemia, Leukemia, 10, SUPPL. 1, (1996)

[36]

Castagnola C., Nozza A., Corso A., Et al., The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement, Haematologica, 82, pp. 577-580, (1997)

[37]

Cairo M.S., Sposto R., Perkins S.L., Et al., Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the Children's Cancer Group experience, Brit J Haematol, 120, pp. 660-670, (2003)

[38]

Gururangan S., Sposto R., Cairo M.S., Et al., Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: A Children's Cancer Group Study, J Clin Oncol, 18, pp. 2017-2025, (2000)

[39]

Patte C., Michon J., Behrendt H., Et al., Results of the LMB 89 protocol for childhood 13-cell lymphoma and leukemia (ALL). Study of the SFOP, Med Pediatr Oncol, 27, (1997)

[40]

Reiter A., Schrappe M., Tiemann M., Et al., Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy

← 1 2 3 4 5 6 7 →